Trials / Completed
CompletedNCT06221605
Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial
Probiotic Supplementation With BLa80, BL21, and LRa05 Stabilizes Lipid Metabolism in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide: A Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Wecare Probiotics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B. The main question it aims to answer is: • Conventional antiviral therapy combined with a 3-month probiotic intervention was used to evaluate the clinical efficacy of reducing HBV infection levels (HBeAg, HBsAg, and HBV DNA levels) and regulating gut microbiota.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Probiotic | The intervention lasted for 3 months and 3 visits (at 0 month, 3rd and 6th month respectively). |
Timeline
- Start date
- 2024-03-30
- Primary completion
- 2025-03-10
- Completion
- 2025-04-11
- First posted
- 2024-01-24
- Last updated
- 2025-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06221605. Inclusion in this directory is not an endorsement.